Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will acquire Verve Therapeutics for about $1.3 billion, taking ownership of a pipeline of in vivo gene-editing candidates aimed at cardiovascular…
Eli Lilly said on Tuesday it would acquire Verve Therapeutics for up to $1.3 billion to gain access to the biotech's experimental one-time gene-editing…
Interim Phase 1b Heart-2 data (May 25, 2026): a single dose of VERVE-102 reduced PCSK9 by 51-88% and LDL-C by up to 62% (1.0 mg/kg cohort), with effects…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Lilly agreed to acquire Verve Therapeutics for $10.50/share at closing (~$1.0B equity) plus CVR up to $3.00/share ($300M) tied to VERVE-102 milestones, total up to ~$1.3B. Gains Verve's gene-editing pipeline targeting ASCVD with one-time treatment potential. Completed July 25, 2025. Post-close, on May 25, 2026 Lilly reported positive interim Phase 1b Heart-2 data for VERVE-102: a single dose reduced PCSK9 by up to 88% and LDL-C by up to 62% (1.0 mg/kg cohort), durable to 18 months with no dose-limiting toxicities (n=35); a Phase 2 study is planned to begin enrolling by end of 2026 -- validating the one-time PCSK9 base-editing thesis behind the CVR milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Verve Therapeutics, Inc. (this deal) | 2025 | $1.3B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2025 deals · Eli Lilly and Company deals · Cardiovascular deals